AstraZeneca's MedImmune is joining the likes of Vanderbilt University and GlaxoSmithKline as a member of the Human Vaccines Project, the company announced Tuesday. The public-private partnership, incubated at the International AIDS Vaccine Initiative (IAVI), aims to accelerate the development of vaccines and immunotherapies against major infectious diseases and cancers "by decoding the human immune system."
AstraZeneca's MedImmune has licensed a toll-like receptor agonist from 3M, in the hopes that intratumoral injection of the candidate will allow the compound to be retained in cancerous tumors, which would improve its tolerability and provide immune system activation.
AstraZeneca's big MedImmune subsidiary has nailed down its third pact in 5 days, inking a collaboration with Inovio Pharmaceuticals on a cancer vaccine designed to generate a tumor-specific T cell response. MedImmune is handing over a $27.5 million upfront and up to $700 million in milestones for the deal while agreeing to also cover the research tab.
Two Maryland-based companies are racing to get a vaccine for respiratory syncytial virus to market--and one just picked up a regulatory boost.
An Investigational New Drug application for WuXi PharmaTech and MedImmune's novel anti-IL6 monoclonal antibody for rheumatoid arthritis was accepted for review by the China Food and Drug Administration, the company said this week, marking a milestone in a development partnership started less than three years ago.
AstraZeneca wants to build up its oncology presence, and its latest acquisition could help the company on its way. The drugmaker's MedImmune division shelled out $150 million upfront and additional milestone payments for Definiens, a diagnostic outfit with imaging technology that identifies biomarkers in tumor tissue and provides a more accurate way to assess tissue samples.
Inovio Pharmaceuticals, AstraZeneca's MedImmune and the University of Pennsylvania have joined forces to study influenza and antibiotic-resistant bacteria, drawing on $12.2 million in federal funds.
It's one step back, one step forward for AstraZeneca's key respiratory drug benralizumab.
AstraZeneca was forced to concede a clinical defeat on Monday, noting that one of its top respiratory drugs in the clinic failed a study for severe chronic obstructive pulmonary disease. But while investigators also flagged a higher rate of adverse events for benralizumab than the placebo arm, the pharma giant shows no signs of backing away from a treatment it's billed as a potential $2 billion per year product.
AstraZeneca has launched a Phase III test of its targeted IL-13 asthma drug tralokinumab, beefing up its late-stage pipeline for respiratory diseases and squaring off against some major league competition now in the clinic.